Cargando…

Brief Report: Enhancement of Patient Recruitment in Rheumatoid Arthritis Clinical Trials Using a Multi‐Biomarker Disease Activity Score as an Inclusion Criterion

OBJECTIVE: Rheumatoid arthritis (RA) clinical trials often exclude patients who have low C‐reactive protein (CRP) levels, which slows enrollment into the trial. The purpose of this study was to determine whether high Multi‐Biomarker Disease Activity (MBDA) scores (>44) in RA patients with low CRP...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Vollenhoven, Ronald F., Bolce, Rebecca, Hambardzumyan, Karen, Saevarsdottir, Saedis, Forslind, Kristina, Petersson, Ingemar F., Sasso, Eric H., Hwang, C. C., Segurado, Oscar G., Geborek, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061088/ https://www.ncbi.nlm.nih.gov/pubmed/26213309 http://dx.doi.org/10.1002/art.39274

Ejemplares similares

A Multi‐Biomarker Disease Activity Score and the Choice of Second‐Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure
por: Hambardzumyan, Karen, et al.
Publicado: (2017)

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial
por: Hambardzumyan, Karen, et al.
Publicado: (2016)

Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial
por: Levitsky, Adrian, et al.
Publicado: (2017)

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial
por: Hambardzumyan, Karen, et al.
Publicado: (2015)

Does autoimmune thyroid disease affects rheumatoid arthritis disease activity or response to methotrexate?
por: Waldenlind, Kristin, et al.
Publicado: (2020)

Comorbidities and treatment patterns in early rheumatoid arthritis: a nationwide Swedish study
por: Tidblad, Liselotte, et al.
Publicado: (2022)

Remaining Pain in Early Rheumatoid Arthritis Patients Treated With Methotrexate
por: Altawil, Reem, et al.
Publicado: (2016)

Sleep problems in rheumatoid arthritis over 12 years from diagnosis: results from the Swedish EIRA study
por: Lyne, Lauren, et al.
Publicado: (2022)

Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial
por: Rezaei, Hamed, et al.
Publicado: (2013)

Occupational exposure to asbestos and silica and risk of developing rheumatoid arthritis: findings from a Swedish population-based case-control study
por: Ilar, Anna, et al.
Publicado: (2019)

Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA
por: Platten, Michael, et al.
Publicado: (2017)

Infliximab Versus Conventional Combination Treatment and Seven‐Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial
por: Eriksson, Jonas K., et al.
Publicado: (2016)

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
por: Chatzidionysiou, Katerina, et al.
Publicado: (2016)

Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial
por: Saevarsdottir, Saedis, et al.
Publicado: (2015)

Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts
por: Westerlind, Helga, et al.
Publicado: (2023)

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial
por: van Vollenhoven, R. F., et al.
Publicado: (2015)

Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists
por: Lesuis, N, et al.
Publicado: (2016)

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2016)

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2016)

Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies
por: Fleischmann, Roy, et al.
Publicado: (2017)

Brief Report: Proatherogenic Cytokine Microenvironment in the Aortic Adventitia of Patients With Rheumatoid Arthritis
por: Ahmed, Ammad, et al.
Publicado: (2016)

Dietary Intake of Polyunsaturated Fatty Acids and Pain in Spite of Inflammatory Control Among Methotrexate‐Treated Early Rheumatoid Arthritis Patients
por: Lourdudoss, Cecilia, et al.
Publicado: (2018)

Identification of Distinct Disease Activity Trajectories in Methotrexate‐Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty‐Four Months
por: Bykerk, Vivian P., et al.
Publicado: (2021)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Brief Report: Deficient Thymic Output in Rheumatoid Arthritis Despite Abundance of Prethymic Progenitors
por: Wagner, Ulf, et al.
Publicado: (2013)

Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial
por: Kastbom, Alf, et al.
Publicado: (2016)

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6
por: van Vollenhoven, Ronald F., et al.
Publicado: (2018)

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
por: Cohen, Stanley B, et al.
Publicado: (2021)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

How to enhance recruitment of individuals at risk of rheumatoid arthritis into trials aimed at prevention: understanding the barriers and facilitators
por: van Boheemen, Laurette, et al.
Publicado: (2021)

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39
por: Spiliopoulou, Athina, et al.
Publicado: (2019)

Brief Report: Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the At‐Risk and Earliest Phases of Rheumatoid Arthritis
por: Rodríguez‐Carrio, Javier, et al.
Publicado: (2016)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020)

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial
por: van Vollenhoven, Ronald, et al.
Publicado: (2020)

Inclusion of Synovial Tissue–Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatment‐Naive Rheumatoid Arthritis Patients
por: Alivernini, Stefano, et al.
Publicado: (2021)

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
por: Kerschbaumer, Andreas, et al.
Publicado: (2020)

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
por: Emamikia, Sharzad, et al.
Publicado: (2016)

Brief Report: Estimating Disease Activity Using Multi‐Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab
por: Fleischmann, Roy, et al.
Publicado: (2016)

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis
por: van Vollenhoven, Ronald, et al.
Publicado: (2019)

Brief Report: Identification of BACH2 and RAD51B as Rheumatoid Arthritis Susceptibility Loci in a Meta-Analysis of Genome-Wide Data
por: McAllister, Kate, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9vvp4rp7ni8on5fejen9vdi0rt